{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:58:18Z","timestamp":1778263098260,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.ijantimicag.2004.07.006","type":"journal-article","created":{"date-parts":[[2004,10,5]],"date-time":"2004-10-05T15:09:06Z","timestamp":1096988946000},"page":"89-92","source":"Crossref","is-referenced-by-count":9,"title":["Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections"],"prefix":"10.1016","volume":"25","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas J.","family":"Biedenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Streit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2004.07.006_bib1","series-title":"Mandell, Douglas and Bennett's. Principals and practice of infectious diseases","article-title":"Urinary tract infections","author":"Sobel","year":"2000"},{"key":"10.1016\/j.ijantimicag.2004.07.006_bib2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/clinids\/6.3.328","article-title":"Staphylococcus saprophyticus as a common cause of urinary tract infections","volume":"6","author":"Hovelius","year":"1984","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.ijantimicag.2004.07.006_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0149-2918(02)85125-6","article-title":"Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin","volume":"24","author":"Guay","year":"2002","journal-title":"Clin Ther"},{"issue":"Suppl 12","key":"10.1016\/j.ijantimicag.2004.07.006_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00006454-200003000-00001","article-title":"Summary: role of a new oral cephalosporin, cefdinir, for therapy of infections of infants and children","volume":"19","author":"Klein","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2004.07.006_bib5","unstructured":"Package insert. Omnicef (cefdinir). Chicago IL. [ABBOTT LABORATORIES web site]. February, 2001. Available at http:\/\/www.rxabbott.com\/pdf\/omnicef.PDF. Accessed on April 17, 2004."},{"key":"10.1016\/j.ijantimicag.2004.07.006_bib6","unstructured":"National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial tests for bacteria that grows aerobically. Approved standard M7-A6. Wayne, PA: NCCLS; 2003."},{"key":"10.1016\/j.ijantimicag.2004.07.006_bib7","unstructured":"National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Supplemental tables, M100-S14. Wayne, PA: NCCLS; 2004."},{"key":"10.1016\/j.ijantimicag.2004.07.006_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1086\/380640","article-title":"Multidrug-resistant Escherichia coli clonal groups causing community-acquired pyelonephritis","volume":"38","author":"Manges","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2004.07.006_bib9","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0924-8579(03)00229-2","article-title":"Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe","volume":"22","author":"Kahlmeter","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2004.07.006_bib10","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S0924-8579(03)00238-3","article-title":"Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection","volume":"22","author":"Hooton","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2004.07.006_bib11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1086\/345754","article-title":"Susceptibility of antimicrobial resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin","volume":"36","author":"Karlowsky","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2004.07.006_bib12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1136\/adc.88.5.444","article-title":"Increasing antibiotic resistance among urinary tract isolates","volume":"88","author":"Ladhani","year":"2003","journal-title":"Arch Dis Child"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2004.07.006_bib13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1469-0691.2000.tb02047.x","article-title":"The new oral cephalosporins in community-acquired infections","volume":"6","author":"Low","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2004.07.006_bib14","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1097\/00006454-200012001-00008","article-title":"Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin\/clavulanate potassium, cefprozil and azithromycin in pediatric patients","volume":"19","author":"Powers","year":"2000","journal-title":"Pediat Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2004.07.006_bib15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0732-8893(03)00165-2","article-title":"Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared to other orally administered antimicrobials tested against common respiratory tract pathogens","volume":"47","author":"Sader","year":"2003","journal-title":"Diag Microbiol Infect Dis"},{"issue":"Suppl 1A","key":"10.1016\/j.ijantimicag.2004.07.006_bib16","doi-asserted-by":"crossref","first-page":"55S","DOI":"10.1016\/S0002-9343(02)01060-4","article-title":"Urinary tract infection at the age extremes: pediatrics and geriatrics","volume":"113","author":"Shortliffe","year":"2002","journal-title":"Am J Med"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2004.07.006_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1469-0691.2000.tb02049.x","article-title":"Oral cephalosporins in uncomplicated urinary tract infections","volume":"6","author":"Garcia-Rodriguez","year":"2000","journal-title":"Clin Microbiol Infect"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857904002997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857904002997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,3]],"date-time":"2019-02-03T06:50:27Z","timestamp":1549176627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857904002997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0924857904002997"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2004.07.006","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}